Approval is for tremelimumab in combination with durvalumab and platinum-based chemotherapy
Drug approved for non-small cell lung cancer with mutation leading to MET exon 14 skipping
Drug was to be used alongside chemotherapy for patients with metastatic non-small cell lung cancer
Lumakras is approved for use in adults with KRAS G12C-mutated non-small cell lung cancer
Cosela reduces the frequency of bone marrow suppression caused by chemotherapy for extensive-stage small cell lung cancer
Current approval of the once-daily tablet indicated for patients who have undergone complete tumor removal